GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (NAS:KTRA) » Definitions » Cash Flow from Investing

Kintara Therapeutics (Kintara Therapeutics) Cash Flow from Investing : $-0.02 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Kintara Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Kintara Therapeutics spent $0.02 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Kintara Therapeutics spent $0.02 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Kintara Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Kintara Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Cash Flow from Investing Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.96 - -0.23

Kintara Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.02

Kintara Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Kintara Therapeutics's Cash Flow from Investing for the fiscal year that ended in Jun. 2023 is calculated as:

Kintara Therapeutics's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kintara Therapeutics  (NAS:KTRA) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Kintara Therapeutics's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.02 Mil. It means Kintara Therapeutics spent $0.02 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Kintara Therapeutics's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Kintara Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Kintara Therapeutics's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Kintara Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Kintara Therapeutics's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Kintara Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Kintara Therapeutics's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Kintara Therapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Kintara Therapeutics's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Kintara Therapeutics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Kintara Therapeutics's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Kintara Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Kintara Therapeutics's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Kintara Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Kintara Therapeutics's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Kintara Therapeutics paid $0.00 Mil for other investing activities.


Kintara Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (Kintara Therapeutics) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Executives
Robert Hoffman director, officer: President and CEO ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Anthony Scott Praill officer: Chief Financial Officer 2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3
Saiid Zarrabian director, officer: Head of Strategic Partnerships P.O. BOX 675765, RANCHO SANTA FE CA 92067
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Toth Robert Joseph Jr director 543 LOMBARD ST, SAN FRANCISCO CA 94133
Dennis M Brown officer: Chief Scientific Officer 100 SAN MATEO DR, MENLO PARK CA 94025
Keith Murphy director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
John Liatos director, officer: SVP, Business Development 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
John K Bell director 38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8
Napoleone Ferrara director 550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101
Lynda Sarah Cranston director 4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3
Erich Mohr director 8300 GREENSBORO DRIVE, MCLEAN VA 22102
Jeffrey Bacha director SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010